Investigating the Effects of Tube Feeds on Glycemia and Sleep in Adults With Cystic Fibrosis-Related Diabetes
NCT06700889
Recruiting
The goal of this at-home, remote study is to understand how tube feeding affects blood sugars and sleep in adults living with Cystic Fibrosis Related Diabetes (CFRD).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
11/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis Related Diabetes, Hyperglycaemia, Insomnia, Cardiometabolic Diseases, Circadian Rhythm Disorders
Register for Updates
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
NCT01860339
Recruiting
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, th... Read More
Gender:
ALL
Ages:
Between 6 years and 30 years
Trial Updated:
11/21/2024
Locations: University of California Davis, Sacramento, California +5 locations
Conditions: Huntington's Disease
Register for Updates
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
NCT04166877
Recruiting
Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in dec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: UC Davis Health, Sacramento, California
Conditions: Trauma, Acute Pain
Register for Updates
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
NCT05312255
Recruiting
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Register for Updates
A Study of Photobiomodulation (PBM) Therapy in People with Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
NCT05675930
Recruiting
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Gender:
ALL
Ages:
4 years and above
Trial Updated:
11/21/2024
Locations: National Institute of Health (Data Collection AND Specimen Analysis), Bethesda, Maryland +9 locations
Conditions: Graft-Versus-Host Disease, GVHD, Undefined
Register for Updates
Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents
NCT05874479
Recruiting
Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/21/2024
Locations: NYU Langone Health, New York, New York
Conditions: Blood Pressure
Register for Updates
Characterization and Clinical Trial of a Variable Friction Shoe
NCT06234124
Recruiting
More than one million Americans present with foot drop after stroke. As the aging population grows in the United States and across the world, incidence of stroke will grow as age is a key risk factor, thus there will be a need for low-cost, easy-to-use, and scalable solutions to administer proper therapy to promote recovery. This study will evaluate a Variable Friction shoe (VF shoe), a new low-cost medical device, for foot drop in an at-home setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Stroke
Register for Updates
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
NCT06569680
Recruiting
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: University of Miami, Miami, Florida
Conditions: Extranodal Marginal Zone Lymphoma
Register for Updates
Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis
NCT06701084
Recruiting
The goal of this study is to discover new genetic causes of infantile epilepsies and evaluate the impact of these discoveries on infants with epilepsy and their families.
Gender:
ALL
Ages:
All
Trial Updated:
11/21/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Neonatal Epilepsy, Infantile Epilepsy
Register for Updates
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
MALE
Ages:
21 years and above
Trial Updated:
11/21/2024
Locations: University of Alabama-Birmingham, Birmingham, Alabama +120 locations
Conditions: Prostate Cancer
Register for Updates
Semantic Feature Analysis Treatment for Aphasia
NCT04215952
Recruiting
This randomized controlled comparative effectiveness study examines manipulation of a key component of an established and efficacious treatment for naming impairments in aphasia, along with cognitive and brain correlates of treatment success. Study participants will be randomly assigned to one of two treatment conditions comparing two different versions of Semantic Feature Analysis treatment. Their performance on standardized and study-specific measures will be used to determine which version of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
Conditions: Aphasia
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Birmingham, Alabama +37 locations
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates